SCHEMBL497514

SCHEMBL497514

Nc1ccc(-c2cc(N)nc3ccc(Cl)cc23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.49
AURKA O14965 1/20 0.48
AURKB Q96GD4 1/20 0.48
APP P05067 2/20 0.46
HSP90AB1 P08238 1/20 0.46
BACE1 P56817 3/20 0.45
ELANE P08246 1/20 0.44
ACHE P22303 5/20 0.41
BCHE P06276 4/20 0.41
GRIN1 Q05586 4/20 0.41
GRIN2A Q12879 4/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 2/20 0.41
GAA P10253 2/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
NPC1 O15118 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL497480 0.89 MAPK1 (0.61) MAPK1AURKAAURKBBACE1ELANE
SCHEMBL497205 0.78 AURKA (0.43) MAPK1AURKAAURKBAPPHSP90AB1
SCHEMBL4658374 0.78 ALDH1A1 (0.44) MAPK1AURKAAURKBAPPHSP90AB1
SCHEMBL11140622 0.75 GRM2 (0.45) BACE1ACHEBCHEALDH1A1GAA
SCHEMBL8410911 0.73 MAPK1 (0.82) MAPK1AURKAAURKBELANEALDH1A1
SCHEMBL3268543 0.73 ACHE (0.45) MAPK1HSP90AB1BACE1ACHEBCHE
SCHEMBL3266785 0.73 ACHE (0.45) HSP90AB1BACE1ACHEBCHEGRIN1
SCHEMBL11826284 0.71 MAPK1 (0.65) MAPK1AURKAAURKBELANEALDH1A1
SCHEMBL8956330 0.71 MAPK1 (0.85) MAPK1AURKAAURKBELANEALDH1A1
SCHEMBL11826655 0.71 DHODH (0.52) MAPK1AURKAAURKBHSP90AB1ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1999112-B1 SUBSTITUTED 2-AMINO-4-PHENYL-DIHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM SANOFI SA (FR) 2015-04-22 EP disclosed
US-8106204-B2 Substituted 2-amino-4-phenyldihydroquinolines, processes for their preparation, pharmaceutical compositions and methods for their use SANOFI-AVENTIS (FR) 2012-01-31 US disclosed
US-20090118329-A1 Novel Substituted 2-Amino-4-Phenyldihydroquinolines, Processes for their Preparation, Pharmaceutical Compositions and Methods for Their Use SANOFI-AVENTIS (FR) 2009-05-07 US disclosed
CN-101395137-A Substituted 2-amino-4-phenyl-dhydroquinolines, method for the production thereof, use thereof as medicaments, and medicaments containing them SANOFI AVENTIS (FR) 2009-03-25 CN disclosed
EP-1999112-A2 SUBSTITUTED 2-AMINO-4-PHENYL-D HYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM Sanofi-Aventis (FR) 2008-12-10 EP disclosed
WO-2007107246-A2 SUBSTITUTED 2-AMINO-4-PHENYL-DιHYDROQUINOLINES, METHOD FOR THE PRODUCTION THEREOF, USE THEREOF AS MEDICAMENTS, AND MEDICAMENTS CONTAINING THEM SANOFI-AVENTIS (DE) 2007-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118329-A1 Novel Substituted 2-Amino-4-Phenyldihydroquinolines, Processes for their Preparation, Pharmaceutical Compositions and Methods for Their Use NHERF1, SLC10A1, SLC9A3 MAPK1 2418/4885AURKA 3081/4885AURKB 3165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.